CAST研究课件（PPT 6页）.ppt

CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic ventricular arrhythmias after MI reduces mortality due to arrhythmia Reference The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406–12. CAST: Cardiac Arrhythmia Suppression Trial - TRIAL DESIGN -  Design Multicenter, multinational; initial phase open; main phase randomized, double-blind, placebo-controlled Patients 1725 patients with 6 ventricular premature depolarizations/h (24h Holter recording) and left ventricular ejection fraction 0.55 at 90 days after MI or 0.40 at 90 days after MI Follow up and primary end point Mean 10 months follow up. Primary endpoint death from arrhythmia Treatment Open titration phase (mean 15 days) to select patients in whom drug (encainide, flecainide or moricizine) suppressed arrhythmias Selected patients then randomized to three-times daily placebo, encainide 35–50 mg, flecainide 100 mg or moricizine 200–250 mg (results for moricizine not reported here) CAST: Cardiac Arrhythmia Suppression Trial- RESULTS - Study of encainide/flecainide vs. placebo halted at mean follow up of 10 months on recommendation of CAST Data and Safety Monitoring Board because in group taking encainide or flecainide, compared with placebo group: All-cause mortality significantly higher Non-fatal cardiac arrest or death from arrhythmia significantly higher Death from other cardiac causes also higher Results consistent across all subgroups examined No confounding factors were identified to explain marked differences between encainide/flecainide and placebo Study subsequently modified to continue with moricizine (CAST II) CAST: Cardiac Arrhythmia Suppression Trial- RESULTS continued- CAST: Cardiac Arrhythmia Suppression Trial-